ReST Therapeutics
  • Home
  • Our Science
  • Our Team
  • Contact Us
Select Page

ReST Results on Alzheimer to be presented at AD/PD 2021

by Gilles Rubinstenn | Dec 4, 2020 | News

Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases: Mechanisms, Clinical Strategies and promising Treatments...

First Results on FENM published in International Journal of Neuropsychopharmacology

by Gilles Rubinstenn | Sep 29, 2020 | News

International Journal of Neuropsychopharmacology (2020) XX(XX): 1–16; pyaa075, https://doi.org/10.1093/ijnp/pyaa075 Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer’s Disease. Simon Couly, Morgane...
Next Entries »

ReST Therapeutics SAS

Capital €20.520889 773 941 R.C.S. Paris
73 rue de Vaugirard
75006 Paris, France

ReST Therapeutics US

BioLabs New Haven
101 College Street
New Haven, CT 06510

  • Home
  • Our Science
  • Our Team
  • Contact Us